Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

SuperGen Will Pursue Orathecin As Combo Therapy Following NDA Withdrawal

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

SuperGen may develop Orathecin as combo therapy following NDA withdrawal. Firm withdrew application in advance of anticipated negative action from FDA. SuperGen is moving ahead with a combination trial with gemcitabine

You may also be interested in...



SuperGen Nixes Phase III For Orathecin Combination Use In Pancreatic Cancer

SuperGen is pulling the plug on plans for a randomized Phase III trial of its Orathecin combination therapy in first-line pancreatic cancer after a Phase II study fell short of a pre-specified threshold for median survival

SuperGen withdraws Orathecin EU application

SuperGen has withdrawn its European marketing authorization application for its oral pancreatic cancer agent Orathecin (rubitecan), the firm announces Jan. 20. The oral camptothecin's future appears to hinge on an ongoing U.S. Phase II trial looking at Orathecin in combination with gemcitabine in the first-line pancreatic cancer setting. "SuperGen intends to make a decision on future development or the alternative disposition of Orathecin based on a review of the interim results of this trial, expected to occur during the first half of 2006," the firm says. In January 2005, SuperGen withdrew an NDA seeking a monotherapy claim for Orathecin, citing FDA's focus on statistical versus clinical benefit (1Pharmaceutical Approvals Monthly January 2005, p. 39). The firm had expected a more favorable stance from EMEA, but the European agency raised several "major concerns" and said it "considers that the overall risks of the product were higher than the benefits to patients"...

SuperGen Plans Dacogen Bone Marrow Disorder NDA; Pharmion Files Vidaza

The "state of the art" clinical trials in SuperGen’s Dacogen NDA for myelodysplastic syndrome may give the product an edge over Pharmion’s pending MDS agent, Vidaza, SuperGen claims.

Topics

UsernamePublicRestriction

Register

LL1133833

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel